The outlook revision reflects Moody’s Investors Service’s expectation that ORMC will sustain its improved operating performance, which will enable it to strengthen its balance sheet.
Moody’s also affirmed ORMC’s “Ba1” rating, affecting $308 million of outstanding debt. The rating affirmation is based on ORMC’s growing market share, improved performance and solid volume growth.
More articles on healthcare finance:
GAO proposes HHS do more to reduce Medicare appeals
S&P revises Doylestown Hospital’s outlook to negative
Moody’s downgrades Mercy Health’s rating to ‘A2’
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
